Patient- and Clinician-Reported Outcomes in Human Papillomavirus-Associated Tonsillar Carcinoma Treated With Unilateral and Bilateral Intensity Modulated Radiation Therapy–A Substudy From TROG 12.01

McDowell, Lachlan; Rischin, Prof Danny; King, Madeleine; Kenny, Lizbeth; Porceddu, Sandro; Wratten, Christopher; Macann, Andrew; Jackson, James E.; Bressel, Mathias; Fua, Tsien; Lin, Charles; Liu, Chen; Corry, June

doi:10.1016/j.ijrobp.2022.08.006

Search citation statements

Order By: Relevance

Paper Sections

Select...

Tools Needed To Measure the Benefit Of Deintensification App...1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, unilateral vs. bilateral neck radiotherapy might be expected to provide improved functional outcomes. However, TROG 12.01 trial data reported by McDowell et al [57] failed to show any clinically relevant differences in radiotherapy symptom severity score between patients who received unilateral vs. bilateral neck radiotherapy across the longitudinal trajectory.…”

Section: Tools Needed To Measure the Benefit Of Deintensification App...mentioning

confidence: 91%

Are we ready for deintensification in human papillomavirus-positive oropharyngeal carcinomas?

Huang

Hahn

Salunkhe

et al. 2023

Current Opinion in Otolaryngology &Amp; Head &Amp; Neck Surgery

View full text Add to dashboard Cite

Purpose of reviewExcellent outcomes following contemporary treatment of human papillomavirus (HPV)-positive oropharyngeal carcinoma (HPVþ OPC) have prompted the exploration of deintensification approaches to minimize treatment-related toxicities. This review describes the landscape of deintensification to date (up to November 2022). Recent findingsAlthough several deintensification trials have been published, none are practice changing. Three phase III randomized-controlled trials studying cetuximab and radiation therapy vs. standard chemoradiotherapy all showed inferior outcomes. Although some phase II trials reported favourable outcomes, they are often single-arm trials without an adequate control arm, thereby limiting the ability to modify practice.

show abstract

Section: Tools Needed To Measure the Benefit Of Deintensification App...mentioning

confidence: 91%